| Value | ₹0.01 Cr |
|---|---|
| Execution period | On or before end of first half of the FY 2026-27 |
NSE filing, NSE: GKSL. Summary written from the filing by ALFA Finder's alert engine.
Gujarat Kidney and Super Speciality Ltd: key numbers
- Share price
- ₹171.50
- Market cap
- ₹1,352 Cr
- Revenue (annual)
- ₹82.01 Cr
- Net profit (annual)
- ₹15.50 Cr
- P/E (TTM)
- 85.4×Sector 52.0×
- Promoter holding
- 71.45%+0.00% QoQ
- FII holding
- 6.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gujarat Kidney and Super Speciality Ltd
All →Gujarat Kidney and Super Speciality Board Meeting Date
Gujarat Kidney will hold a board meeting on 04 Nov 2026 to consider unaudited quarterly results. The trading window closes from 01 Oct 2026.
Gujarat Kidney and Super Speciality Other Announcement
This is a routine quarterly shareholding pattern disclosure for the period ended September 30, 2026, filed under SEBI Regulation 31.
Gujarat Kidney and Super Speciality Annual General Meeting
Gujarat Kidney and Super Speciality Limited held its 7th Annual General Meeting on September 28, 2026. Shareholders approved financial statements, director appointments, and various regulatory borrowing and investment limits.
Gujarat Kidney and Super Speciality Annual Report
Gujarat Kidney and Super Speciality Limited issued a corrigendum to its FY 2025-26 Annual Report. The update includes missing Secretarial Audit observations and management responses.
Gujarat Kidney and Super Speciality Annual General Meeting
Gujarat Kidney and Super Speciality Limited has issued a notice for its 7th Annual General Meeting scheduled for September 28, 2026. The meeting will address financial statements, director appointments, and related party transactions.
- Value
- ₹1.78 Cr
Gujarat Kidney and Super Speciality Annual General Meeting
Gujarat Kidney and Super Speciality Limited filed a revised Annual Report for FY 2025-26. The document also includes the notice for its 7th Annual General Meeting.
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.